CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer. 2012 Jan 12; Authors: Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Cha… [...]
|
|||||||
|
You are at Home>>Cancers>>Cervical & Ovarian Cancer>> Noninvasive Imaging Reveals Inhibition of Ovarian Cancer by Targeting CXCL12-CXCR4. Neoplasia. 2011 Dec;13(12):1152-61 Authors: Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, Luker GD Abstract Patients wi… [...] Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol. 2012 Jan 11;6(1):3 Authors: Ben-Hamo R, Efroni S Abstract ABSTRACT: BAC… [...] Medicaid enrollment at early stage of disease: the breast and cervical cancer prevention and treatment act in Georgia. Inquiry. 2011;48(3):197-208 Authors: Chien LN, Adams EK, Yang Z Abstract This study linke… [...] Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol. 2012;2012:915140 Authors: Sawada K, Ohyagi-Hara C, Kimura T, Morishige K Abstract Ovarian cancer is a deadly disease, with a cure rate … [...] Value of Magnetic Resonance and 18FDG PET-CT in Predicting Tumor Response and Resectability of Primary Locally Advanced Cervical Cancer After Treatment With Intensity-Modulated Arc Therapy: A Prospective Pathology-Matched Study. Int … [...] Fertility-Sparing Surgery for Early Cervical Cancer-Approach to Less Radical Surgery. Int J Gynecol Cancer. 2012 Jan 10; Authors: Raju SK, Papadopoulos AJ, Montalto SA, Coutts M, Culora G, Kodampur M, Mehra G, Devaja O … [...] |
|||||||
|
Copyright © 2012 Science Today Online - All Rights Reserved Google PR: 0 · Alexa Rank: 0 |
|||||||
Recent Comments